| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
WWL123 targets α/β-hydrolase domain 6 (ABHD6), a serine hydrolase that catalyzes the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). By inhibiting ABHD6, WWL123 increases the levels of 2-AG, which activates cannabinoid receptors CB1 and CB2. This leads to the modulation of various signaling pathways involved in inflammation, pain, and neuronal excitability. WWL123 is a brain-penetrant compound, allowing it to exert its effects in the central nervous system.
|
|---|---|
| ln Vitro |
WWL123 is a potent inhibitor of ABHD6 with an IC50 of 0.43 µM. It is selective for ABHD6, showing >10-fold selectivity over a panel of ~35 other serine hydrolases. The compound is brain-penetrant, making it suitable for studying the role of ABHD6 in the central nervous system.
|
| ln Vivo |
WWL123 has been shown to decrease seizure incidence in a genetic mouse model of juvenile Huntington's disease as well as in chemically-induced epilepsy models. It blocks pentylenetetrazole (PTZ)-induced seizures in healthy mice and spontaneous seizures in R6/2 mice. These findings demonstrate the in vivo efficacy of WWL123 in models of epilepsy and Huntington's disease.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for WWL123 typically involves measuring its inhibitory activity against ABHD6 using a fluorogenic substrate. The compound is incubated with the enzyme and the substrate, and the release of the fluorescent product is measured. The IC50 value is determined from the dose-response curve. Selectivity is assessed by testing the compound against a panel of other serine hydrolases.
|
| Cell Assay |
The in vitro cellular assay for WWL123 typically involves culturing cells that express ABHD6, such as neurons or microglia. Cells are treated with varying concentrations of the compound, and the levels of 2-AG are measured by LC-MS/MS. The compound's effects on downstream signaling pathways, such as the activation of cannabinoid receptors, can also be assessed.
|
| Animal Protocol |
In vivo animal studies for WWL123 typically involve the use of mouse models of epilepsy or Huntington's disease. In the PTZ-induced seizure model, mice are administered the compound via intraperitoneal injection before PTZ treatment, and the latency to seizure onset and seizure severity are assessed. In the R6/2 mouse model of Huntington's disease, the compound is administered chronically, and spontaneous seizures are monitored.
|
| ADME/Pharmacokinetics |
WWL123 has a molecular weight of 436.5 g/mol and a molecular formula of C28H24N2O3. The IUPAC name is [1,1'-biphenyl]-4-yl ([1,1'-biphenyl]-3-ylmethyl)(methyl)carbamate. The compound is a crystalline solid with a purity of ≥95%. It is soluble in DMSO (1 mg/mL) and should be stored at -20°C. Further detailed PK parameters are not available in the public domain.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for WWL123 are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References | |
| Additional Infomation |
WWL123 is a potent, selective, and brain-penetrant inhibitor of α/β-hydrolase domain 6 (ABHD6). It has an IC50 of 0.43 µM for ABHD6. It is used as a research tool to study the role of ABHD6 in inflammation, metabolic disorders, epilepsy, and Huntington's disease. It has been shown to decrease seizure incidence in mouse models. It has not yet entered clinical trials and is strictly for preclinical research purposes.
|
| Molecular Formula |
C28H24N2O3
|
|---|---|
| Molecular Weight |
436.51
|
| Exact Mass |
436.178
|
| CAS # |
1338574-83-6
|
| PubChem CID |
90209976
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
646.2±55.0 °C at 760 mmHg
|
| Flash Point |
344.6±31.5 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.631
|
| LogP |
5.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
631
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CC1=CC(=CC=C1)C2=CC=CC=C2)C(=O)OC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)N
|
| InChi Key |
UUJGYRHAOHORFC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H24N2O3/c1-30(19-20-6-5-9-25(18-20)21-7-3-2-4-8-21)28(32)33-26-16-14-23(15-17-26)22-10-12-24(13-11-22)27(29)31/h2-18H,19H2,1H3,(H2,29,31)
|
| Chemical Name |
[4-(4-carbamoylphenyl)phenyl] N-methyl-N-[(3-phenylphenyl)methyl]carbamate
|
| Synonyms |
WWL 123; WWL-123; WWL123
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2909 mL | 11.4545 mL | 22.9090 mL | |
| 5 mM | 0.4582 mL | 2.2909 mL | 4.5818 mL | |
| 10 mM | 0.2291 mL | 1.1454 mL | 2.2909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
